China Biologic Products Holdings Inc (NASDAQ:CBPO) Given Consensus Rating of “Hold” by Analysts

Shares of China Biologic Products Holdings Inc (NASDAQ:CBPO) have been assigned a consensus rating of “Hold” from the six ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $90.50.

CBPO has been the subject of a number of research analyst reports. Zacks Investment Research raised China Biologic Products from a “hold” rating to a “buy” rating and set a $128.00 target price for the company in a report on Tuesday. ValuEngine raised China Biologic Products from a “hold” rating to a “buy” rating in a report on Tuesday, October 1st. Finally, BidaskClub raised China Biologic Products from a “hold” rating to a “buy” rating in a report on Tuesday, September 24th.

Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in shares of China Biologic Products during the second quarter valued at $187,000. Nikko Asset Management Americas Inc. boosted its position in shares of China Biologic Products by 101.4% during the second quarter. Nikko Asset Management Americas Inc. now owns 109,599 shares of the biopharmaceutical company’s stock valued at $10,445,000 after buying an additional 55,176 shares during the last quarter. Paradice Investment Management LLC purchased a new stake in shares of China Biologic Products during the second quarter valued at $373,000. Bank of New York Mellon Corp boosted its position in shares of China Biologic Products by 2.1% during the second quarter. Bank of New York Mellon Corp now owns 17,276 shares of the biopharmaceutical company’s stock valued at $1,647,000 after buying an additional 357 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of China Biologic Products during the second quarter valued at $8,749,000. Institutional investors and hedge funds own 36.90% of the company’s stock.

Shares of CBPO opened at $114.99 on Wednesday. China Biologic Products has a 52 week low of $60.08 and a 52 week high of $116.63. The company has a market capitalization of $4.52 billion, a price-to-earnings ratio of 28.60, a PEG ratio of 7.02 and a beta of 1.20. The stock’s 50-day moving average price is $110.62 and its 200-day moving average price is $98.93.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.21. The company had revenue of $135.70 million during the quarter. China Biologic Products had a return on equity of 8.56% and a net margin of 29.46%. The business’s revenue for the quarter was up 12.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.17 EPS. Equities research analysts expect that China Biologic Products will post 3.29 EPS for the current fiscal year.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Featured Article: Understanding each part of a balance sheet

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.